666 related articles for article (PubMed ID: 19602587)
1. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
2. A complex interplay between Akt, TSC2 and the two mTOR complexes.
Huang J; Manning BD
Biochem Soc Trans; 2009 Feb; 37(Pt 1):217-22. PubMed ID: 19143635
[TBL] [Abstract][Full Text] [Related]
3. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.
Huang J; Dibble CC; Matsuzaki M; Manning BD
Mol Cell Biol; 2008 Jun; 28(12):4104-15. PubMed ID: 18411301
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.
Goncharova EA; James ML; Kudryashova TV; Goncharov DA; Krymskaya VP
PLoS One; 2014; 9(10):e111476. PubMed ID: 25360538
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
6. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
7. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
Julien LA; Carriere A; Moreau J; Roux PP
Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
[TBL] [Abstract][Full Text] [Related]
8. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.
Zhang HH; Huang J; Düvel K; Boback B; Wu S; Squillace RM; Wu CL; Manning BD
PLoS One; 2009 Jul; 4(7):e6189. PubMed ID: 19593385
[TBL] [Abstract][Full Text] [Related]
9. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
Misra UK; Pizzo SV
PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
[TBL] [Abstract][Full Text] [Related]
10. mTORC2 is required for proliferation and survival of TSC2-null cells.
Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
[TBL] [Abstract][Full Text] [Related]
11. A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation.
Dalle Pezze P; Sonntag AG; Thien A; Prentzell MT; Gödel M; Fischer S; Neumann-Haefelin E; Huber TB; Baumeister R; Shanley DP; Thedieck K
Sci Signal; 2012 Mar; 5(217):ra25. PubMed ID: 22457331
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
[TBL] [Abstract][Full Text] [Related]
14. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
[TBL] [Abstract][Full Text] [Related]
15. Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia.
Wolff NC; Vega-Rubin-de-Celis S; Xie XJ; Castrillon DH; Kabbani W; Brugarolas J
Mol Cell Biol; 2011 May; 31(9):1870-84. PubMed ID: 21383064
[TBL] [Abstract][Full Text] [Related]
16. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
[TBL] [Abstract][Full Text] [Related]
17. Cystogenesis and elongated primary cilia in Tsc1-deficient distal convoluted tubules.
Armour EA; Carson RP; Ess KC
Am J Physiol Renal Physiol; 2012 Aug; 303(4):F584-92. PubMed ID: 22674026
[TBL] [Abstract][Full Text] [Related]
18. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
García-Martínez JM; Alessi DR
Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
[TBL] [Abstract][Full Text] [Related]
19. The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis.
Kang YJ; Lu MK; Guan KL
Cell Death Differ; 2011 Jan; 18(1):133-44. PubMed ID: 20616807
[TBL] [Abstract][Full Text] [Related]
20. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
